| First Author | Höckendorf U | Year | 2016 |
| Journal | Cancer Cell | Volume | 30 |
| Issue | 1 | Pages | 75-91 |
| PubMed ID | 27411587 | Mgi Jnum | J:233524 |
| Mgi Id | MGI:5784931 | Doi | 10.1016/j.ccell.2016.06.002 |
| Citation | Hockendorf U, et al. (2016) RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. Cancer Cell 30(1):75-91 |
| abstractText | Since acute myeloid leukemia (AML) is characterized by the blockade of hematopoietic differentiation and cell death, we interrogated RIPK3 signaling in AML development. Genetic loss of Ripk3 converted murine FLT3-ITD-driven myeloproliferation into an overt AML by enhancing the accumulation of leukemia-initiating cells (LIC). Failed inflammasome activation and cell death mediated by tumor necrosis factor receptor caused this accumulation of LIC exemplified by accelerated leukemia onset in Il1r1(-/-), Pycard(-/-), and Tnfr1/2(-/-) mice. RIPK3 signaling was partly mediated by mixed lineage kinase domain-like. This link between suppression of RIPK3, failed interleukin-1beta release, and blocked cell death was supported by significantly reduced RIPK3 in primary AML patient cohorts. Our data identify RIPK3 and the inflammasome as key tumor suppressors in AML. |
